MARKET

SBPH

SBPH

Spring Bk Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.190
+0.030
+2.59%
Closed 16:00 02/21 EST
OPEN
1.130
PREV CLOSE
1.160
HIGH
1.222
LOW
1.130
VOLUME
67.77K
TURNOVER
--
52 WEEK HIGH
11.00
52 WEEK LOW
1.100
MARKET CAP
18.08M
P/E (TTM)
-0.8127
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SBPH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SBPH stock price target is 8.55 with a high estimate of 29.00 and a low estimate of 1.500.

EPS

SBPH News

More
  • Spring Bank FY EPS $(1.46) Up From $(1.88) YoY
  • Benzinga · 02/14 14:38
  • Spring Bank Pharmaceuticals Reports 2019 Fourth Quarter and Full-Year Financial Results
  • GlobeNewswire · 02/14 14:37
  • The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs
  • Benzinga · 02/06 12:47
  • The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data
  • Benzinga · 02/05 12:43

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About SBPH

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics for the treatment of viral infections, inflammatory diseases and cancers using its small molecule nucleotide platform. The Company is developing its product inarigivir soproxil (inarigivir), for the treatment of chronic hepatitis B virus (HBV). The Company's inarigivir selectively activates within infected hepatic cells the cellular protein, retinoic acid-inducible gene 1 (RIG-I), to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company also developing a second STING (STimulator of INterferon Genes) agonist product candidate, SB 11285, which is an immunotherapeutic agent for the potential treatment of selected cancers. The Company lead product is inarigivir.
More

Webull offers kinds of Spring Bank Pharmaceuticals Inc stock information, including NASDAQ:SBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SBPH stock news, and many more online research tools to help you make informed decisions.